Pricing Log in Create free account

Altimmune, Inc. (ALT) vs REGENXBIO Inc. (RGNX)

Altimmune, Inc. and REGENXBIO Inc. are both Biotechnology companies. Altimmune, Inc. and REGENXBIO Inc. are of similar size ($472.7M and $459.1M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against 12.0%. Altimmune, Inc. has the higher net margin (0.00% vs −112.6%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 18 metrics below, Altimmune, Inc. leads on 12 and REGENXBIO Inc. on 6.

Valuation

Metric ALT RGNX Biotechnology median
P/E n/m n/m 8.50
P/S 8,869.05 2.10 9.71
P/B 0.86 5.10 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2,534.11 1.53 9.21
Earnings yield (35.45%) (54.69%) (33.15%)
Free cash flow yield (18.81%) (68.21%) (25.50%)

Profitability

Metric ALT RGNX Biotechnology median
Gross margin 100.00% 86.38% 65.16%
Operating margin 0.00% (94.08%) 0.00%
Net margin 0.00% (112.58%) 0.00%
Free cash flow margin 0.00% (143.09%) 0.00%
Return on equity (28.87%) (137.63%) (56.36%)
Return on assets (25.58%) (40.60%) (48.04%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT RGNX Biotechnology median
Revenue growth (TTM) 130.00% 12.00% 6.02%
EPS growth (last fiscal year) 25.37% 18.08% 30.26%
Revenue growth, 5-year CAGR (65.33%) 1.97% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT RGNX Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 2.86 4.72
Net debt to EBITDA 2.49 1.58 0.96

Dividend

Metric ALT RGNX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALT RGNX Biotechnology median
Market cap 459.07m 472.65m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack